San Francisco, CA (PRWEB) November 14, 2013
endpoint (http://www.endpointclinical.com), a leader in Integrated Voice Response (IVR) and Integrated Web Response (IWR) systems, announced today its expansion into Europe with a European HQ office expected to open in early 2014. endpoint has doubled its revenue in the past two years and is forecasted to grow 40 percent in 2014.
endpoint is currently working on clinical trials in 40+ countries and the global expansion is seen as a natural progression for the company.
“It has long been our plan with our growing customer base in the Americas and Europe to add more resources in Europe,” said Jonathan Dole, co-founder and CEO, endpoint. “Not only is this a milestone for endpoint, but it also supports our growing European customer base.”
endpoint recently recruited Garrath Read as Director of Global Business Development, to support endpoint’s growth in Europe. Garrath comes from a global CRO background with over 15 years sales/healthcare experience.
“endpoint has been in the enviable position of meeting customers’ needs with a solution that can be implemented significantly faster than any of its competitors ,” said Garrath. “I’m very pleased to work for a company whose sole purpose is to create more efficient clinical trials with the patient being the winner.”
endpoint’s flagship product platform, PULSE, is fully configurable, allowing users to design and deploy clinical trial Integrated Response Technology (IRT) systems while saving 40 percent on the development time of clinical trials.
Endpoint will be exhibiting at the 12th annual Partnerships in Clinical Trials Congress in Vienna, Austria on the 20th-21st of November.
Headquartered in San Francisco, endpoint is an innovative company dedicated to the development of the leading technology platforms for the life sciences industry. endpoint’s founding team has been developing IRT systems for clinical trials since 1998 and have deployed systems to small, medium and large pharmaceutical companies for domestic and global studies with experience across a broad range of therapeutic areas and global implementations. For more information, visit endpoint at http://www.endpointclinical.com.
# # #